Botanix Takeover, page-24

"I remember reading in one of Bot's presentations that there are currently approx 3000 clinically defined derma conditions........so there's no shortage of future derma based targets we might choose to study...."

When speaking to Matt a little while ago regarding 1801, I asked whether cancer had been shown to be a possible candidate. He said it was, but indicated that due to the longer trial & approvals durations, it wouldn't be as commercially attractive for BOT (at their present size & balance sheet) to pursue this. There were obviously several other options which could have been pursued as well.

From my discussion with management and other research, my understanding is that a significant portion of the 3,000 clinically defined derma conditions you refer to are already on the company's radar as future product pipelines, for times when the size & balance sheet DOES allow us to pursue these opportunities..